Moorkens, G, Berwaerts, J, Wynants, H et al. · Clinical endocrinology · 2000 · DOI
This study examined hormone levels in 73 people with ME/CFS compared to 21 healthy people. Researchers found that people with ME/CFS had lower growth hormone (GH) levels, especially at night and when their body was stressed by low blood sugar. They also had higher levels of prolactin and thyroid-stimulating hormone (TSH), suggesting their brain chemistry may be imbalanced. These hormone changes were associated with increased belly fat in ME/CFS patients.
This study provides quantitative evidence of neuroendocrine dysfunction in ME/CFS, particularly GH dysregulation, which may explain the fatigue, exercise intolerance, and metabolic changes patients experience. The findings support biological abnormalities in ME/CFS and suggest that the condition involves measurable alterations in brain-pituitary signaling rather than being purely psychological.
This study does not prove that GH deficiency causes ME/CFS symptoms or that GH replacement would benefit patients. The observation of normal IGF-I levels (GH's main functional mediator) raises questions about the clinical significance of the observed GH reduction. Correlation between hormone changes and visceral fat does not establish causation, and cross-sectional design prevents determination of whether hormonal changes precede symptom onset.
About the PEM badge: “PEM required” means post-exertional malaise was an explicit required diagnostic criterion for participant inclusion in this study — not that PEM was studied, observed, or discussed. Studies using criteria that do not require PEM (e.g. Fukuda, Oxford) are tagged “PEM not required”. How the atlas works →
Spotted an error in this entry? Report it →